Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Clinical trial NCT03881488 · COMPLETED

Trial details

NCT number: NCT03881488
Sponsor: Compass Therapeutics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Locally Advanced Solid Tumor Metastatic Cancer Non-small Cell Lung Cancer Small Cell Lung Cancer Mesothelioma Melanoma Head and Neck Cancer

Start date: 2019-05-17
Primary completion: 2025-05-21
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.